Santhera Pharmaceuticals Holding AG (SANN.SW)
- Previous Close
13.14 - Open
12.98 - Bid 13.80 x --
- Ask 13.80 x --
- Day's Range
12.98 - 13.90 - 52 Week Range
7.21 - 17.76 - Volume
28,559 - Avg. Volume
46,176 - Market Cap (intraday)
178.332M - Beta (5Y Monthly) -0.41
- PE Ratio (TTM)
-- - EPS (TTM)
-3.69 - Earnings Date Apr 29, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
30.00
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
www.santhera.comRecent News: SANN.SW
更多內容Performance Overview: SANN.SW
Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
比較: SANN.SW
選擇以關鍵表現數據分析類似公司；最多可選擇 4 個股份。
Statistics: SANN.SW
更多內容Valuation Measures
Market Cap
178.33M
Enterprise Value
178.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.03
Price/Book (mrq)
6.44
Enterprise Value/Revenue
4.55
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-107.30%
Return on Assets (ttm)
-15.81%
Return on Equity (ttm)
-95.79%
Revenue (ttm)
39.12M
Net Income Avi to Common (ttm)
-41.97M
Diluted EPS (ttm)
-3.69
Balance Sheet and Cash Flow
Total Cash (mrq)
40.92M
Total Debt/Equity (mrq)
146.65%
Levered Free Cash Flow (ttm)
-31.8M